FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126852211> ?p ?o ?g. }

• W3126852211 endingPage "607" @default.
• W3126852211 startingPage "607" @default.
• W3126852211 abstract "Membranous nephropathy (MN) is a rare auto-immune disease where the glomerulus is targeted by circulating auto-antibodies mostly against podocyte antigens, which results in the formation of electron-dense immune complexes, activation of complement and massive proteinuria. MN is the most common cause of nephrotic syndrome in adults leading to severe thrombotic complications and kidney failure. This review is focused on the recent therapeutic and pathophysiological advances that occurred in the last two years. For a long time, we were lacking a head-to-head comparison between cyclophosphamide considered as the gold standard therapy and other medications, notably rituximab. Substantial progress has been achieved owing to three randomized controlled trials. MENTOR (Membranous Nephropathy Trial of Rituximab) and STARMEN (Sequential Therapy with Tacrolimus and Rituximab in Primary Membranous Nephropathy) conclusively established that calcineurin inhibitor-based regimens are slower to result in an immunologic response than rituximab or cyclophosphamide, achieve fewer complete clinical remissions, and are less likely to maintainremission. Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (RI-CYCLO) suggested that competition between cyclophosphamide and rituximab remains open. Given the technological leap combining laser microdissection of glomeruli and mass spectrometry of solubilized digested proteins, four “new antigens” were discovered including NELL-1 and Semaphorin 3B in so-called primary MN, and exostosins 1 and 2 and NCAM 1 in lupus MN. NELL-1 is associated with about 8% of primary MN and is characterized by segmental immune deposits and frequent association with cancer (30%). Semaphorin 3B-associated MN usually occurs in children, often below the age of two years, where it is the main antigen, representing about 16% of non-lupus MN in childhood. Exostosins 1/2 and NCAM 1 are associated with 30% and 6% of lupus MN, respectively. Exostosins 1/2 (EXT1/2) staining is associated with a low rate of end-stage kidney disease (ESKD) even in mixed classes III/IV+V. These findings already lead to revisiting the diagnostic and therapeutic algorithms toward more personalized medicine." @default.
• W3126852211 created "2021-02-15" @default.
• W3126852211 creator A5001178420 @default.
• W3126852211 creator A5014081829 @default.
• W3126852211 creator A5075857334 @default.
• W3126852211 date "2021-02-05" @default.
• W3126852211 modified "2023-10-18" @default.
• W3126852211 title "Advances in Membranous Nephropathy" @default.
• W3126852211 cites W1668085700 @default.
• W3126852211 cites W1983119175 @default.
• W3126852211 cites W1983851911 @default.
• W3126852211 cites W1986167294 @default.
• W3126852211 cites W1988387132 @default.
• W3126852211 cites W2012034410 @default.
• W3126852211 cites W2037144516 @default.
• W3126852211 cites W2045372326 @default.
• W3126852211 cites W2073033781 @default.
• W3126852211 cites W2083760961 @default.
• W3126852211 cites W2097148864 @default.
• W3126852211 cites W2101856382 @default.
• W3126852211 cites W2116986363 @default.
• W3126852211 cites W2127127482 @default.
• W3126852211 cites W2138543166 @default.
• W3126852211 cites W2140565611 @default.
• W3126852211 cites W2141219630 @default.
• W3126852211 cites W2153604508 @default.
• W3126852211 cites W2160326564 @default.
• W3126852211 cites W2166822765 @default.
• W3126852211 cites W2398276384 @default.
• W3126852211 cites W2470335436 @default.
• W3126852211 cites W2532400747 @default.
• W3126852211 cites W2536433913 @default.
• W3126852211 cites W2544842064 @default.
• W3126852211 cites W2603454576 @default.
• W3126852211 cites W2613205117 @default.
• W3126852211 cites W2757242196 @default.
• W3126852211 cites W2765203695 @default.
• W3126852211 cites W2790603736 @default.
• W3126852211 cites W2791067901 @default.
• W3126852211 cites W2810423115 @default.
• W3126852211 cites W2907489347 @default.
• W3126852211 cites W2917492117 @default.
• W3126852211 cites W2938956881 @default.
• W3126852211 cites W2943790844 @default.
• W3126852211 cites W2953848769 @default.
• W3126852211 cites W2955404566 @default.
• W3126852211 cites W2962703330 @default.
• W3126852211 cites W2963389942 @default.
• W3126852211 cites W2968526958 @default.
• W3126852211 cites W2969918635 @default.
• W3126852211 cites W2977665112 @default.
• W3126852211 cites W2981136267 @default.
• W3126852211 cites W2994968732 @default.
• W3126852211 cites W3002141038 @default.
• W3126852211 cites W3003933064 @default.
• W3126852211 cites W3004553062 @default.
• W3126852211 cites W3017309960 @default.
• W3126852211 cites W3034245697 @default.
• W3126852211 cites W3037751623 @default.
• W3126852211 cites W3039129153 @default.
• W3126852211 cites W3049771190 @default.
• W3126852211 cites W3071414982 @default.
• W3126852211 cites W3085025551 @default.
• W3126852211 cites W3091916585 @default.
• W3126852211 cites W3092354966 @default.
• W3126852211 cites W3094954267 @default.
• W3126852211 cites W3095460642 @default.
• W3126852211 cites W3124083971 @default.
• W3126852211 cites W3151337960 @default.
• W3126852211 doi "https://doi.org/10.3390/jcm10040607" @default.
• W3126852211 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7915386" @default.
• W3126852211 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33562791" @default.
• W3126852211 hasPublicationYear "2021" @default.
• W3126852211 type Work @default.
• W3126852211 sameAs 3126852211 @default.
• W3126852211 citedByCount "40" @default.
• W3126852211 countsByYear W31268522112021 @default.
• W3126852211 countsByYear W31268522112022 @default.
• W3126852211 countsByYear W31268522112023 @default.
• W3126852211 crossrefType "journal-article" @default.
• W3126852211 hasAuthorship W3126852211A5001178420 @default.
• W3126852211 hasAuthorship W3126852211A5014081829 @default.
• W3126852211 hasAuthorship W3126852211A5075857334 @default.
• W3126852211 hasBestOaLocation W31268522111 @default.
• W3126852211 hasConcept C126322002 @default.
• W3126852211 hasConcept C128057223 @default.
• W3126852211 hasConcept C159654299 @default.
• W3126852211 hasConcept C203014093 @default.
• W3126852211 hasConcept C2775946357 @default.
• W3126852211 hasConcept C2776694085 @default.
• W3126852211 hasConcept C2776755627 @default.
• W3126852211 hasConcept C2778930706 @default.
• W3126852211 hasConcept C2780091579 @default.
• W3126852211 hasConcept C2780368995 @default.
• W3126852211 hasConcept C2780653079 @default.
• W3126852211 hasConcept C2911091166 @default.
• W3126852211 hasConcept C71924100 @default.
• W3126852211 hasConceptScore W3126852211C126322002 @default.

• next